Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Classificação em ações
#3774
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Preço da ação
$4.87
Valor de mercado
$4.36B
Variação (1 dia)
-5.47%
Variação (1 ano)
-15.62%
País
CN
Negociar Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Categoria
Healthcare
Receita da Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Receita em Oct 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd de 2006 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2025 | $600.18M | 267.03% |
| 2024 | $163.52M | 14.15% |
| 2023 | $143.25M | 19.70% |
| 2022 | $119.67M | -18.11% |
| 2021 | $146.13M | 45.75% |
| 2020 | $100.27M | -40.70% |
| 2019 | $169.09M | 1.82% |
| 2018 | $166.06M | -2.09% |
| 2017 | $169.60M | 22.48% |
| 2016 | $138.47M | 2.49% |
| 2015 | $135.11M | 7.86% |
| 2014 | $125.26M | 4.39% |
| 2013 | $119.99M | 25.65% |
| 2012 | $95.50M | 26.69% |
| 2011 | $75.38M | 45.08% |
| 2010 | $51.96M | 44.63% |
| 2009 | $35.92M | 53.80% |
| 2008 | $23.36M | 84.39% |
| 2007 | $12.67M | 186.16% |
| 2006 | $4.43M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $10.11B | - |
BE
|
|
| $6.02B | - |
NL
|
